Gregory K. Palm
Director/Board Member at Olatec Therapeutics LLC
Profile
Gregory K.
Palm is currently a Director at Olatec Therapeutics LLC since 2021.
Previously, he worked as Secretary, Executive VP & General Counsel at The Goldman Sachs Group, Inc. from 2011 to 2018.
He completed his undergraduate degree at Massachusetts Institute of Technology and his graduate and MBA degrees at Harvard Business School.
Gregory K. Palm active positions
Companies | Position | Start |
---|---|---|
Olatec Therapeutics LLC
Olatec Therapeutics LLC Pharmaceuticals: MajorHealth Technology Olatec Therapeutics LLC is a privately held biopharmaceutical company based in the United States. The American company is in the clinical stage of developing a platform of oral NLRP3 inhibitors to treat and prevent a broad spectrum of acute and chronic inflammatory diseases mediated by IL-1. Olatec's proprietary compounds include approximately 60 analogues being screened as viable drug candidates, and the company has over 140 patents granted covering its compounds. The company's drug development team is comprised of experienced management and international experts in translational medicine with unparalleled expertise in inflammation and immunology. Olatec is conducting clinical trials in the FDA and EMA. The company was founded by Damaris B. Skouras, who has been the CEO since incorporation. | Director/Board Member | 2021-07-28 |
Former positions of Gregory K. Palm
Companies | Position | End |
---|---|---|
THE GOLDMAN SACHS GROUP, INC. | General Counsel | - |
Training of Gregory K. Palm
Massachusetts Institute of Technology | Undergraduate Degree |
Harvard Business School | Graduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 1 |
---|---|
THE GOLDMAN SACHS GROUP, INC. | Finance |
Private companies | 1 |
---|---|
Olatec Therapeutics LLC
Olatec Therapeutics LLC Pharmaceuticals: MajorHealth Technology Olatec Therapeutics LLC is a privately held biopharmaceutical company based in the United States. The American company is in the clinical stage of developing a platform of oral NLRP3 inhibitors to treat and prevent a broad spectrum of acute and chronic inflammatory diseases mediated by IL-1. Olatec's proprietary compounds include approximately 60 analogues being screened as viable drug candidates, and the company has over 140 patents granted covering its compounds. The company's drug development team is comprised of experienced management and international experts in translational medicine with unparalleled expertise in inflammation and immunology. Olatec is conducting clinical trials in the FDA and EMA. The company was founded by Damaris B. Skouras, who has been the CEO since incorporation. | Health Technology |
- Stock Market
- Insiders
- Gregory K. Palm